Truist lowered the firm’s price target on Regeneron (REGN) to $796 from $801 and keeps a Buy rating on the shares. The company’s Q1 earnings boasted top and bottom-line beats, with some persistence of commercial performance in the context of seasonality, the analyst tells investors in a research note. The broader story for Regeneron includes persistent Dupi’ performance and a perpetually expanding pipeline, the firm added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $917 from $923 at Barclays
- Regeneron Earnings Call Highlights Durable Growth Engine
- These Are the Stocks Reporting Earnings Today – April 29, 2026
- Morning Movers: NXP Semi, Bloom Energy charged up after results
- Regeneron reports Q1 adjusted EPS $9.47, consensus $8.90